Augmentation of the restless legs syndrome with carbidopa/levodopa

Sleep

Volumn 19, Issue 3, 1996, Pages 205-213

  Allen, Richard P ^a,b   Earley, Christopher J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Hopkins Sleep Disorders Center   (United States)

Author keywords

Carbidopa; Dopaminergic agents; Levodopa; Periodic limb movements in sleep; Restless legs syndrome

Indexed keywords

CARBIDOPA; CARBIDOPA PLUS LEVODOPA; LEVODOPA;

ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SCREENING; FEMALE; HUMAN; LIMB MOVEMENT; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; POLYSOMNOGRAPHY; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME;

EID: 0029980676     PISSN: 01618105     EISSN: None     Source Type: Journal    
DOI: 10.1093/sleep/19.3.205     Document Type: Article

References (28)

1. Ekbom KA. Restless legs syndrome. Neurology 1960;10:868-73.
2. Bornstein B. Restless legs. Psychiatr Neurol 1961;141:165-201.
3. Diagnostic Classification Steering Committee, Thorpy MJ, chairman. International classification of sleep disorders: diagnostic and coding manual. Rochester, MN: American Sleep Disorders Association, 1990:396.
4. Walters A, Aldrich M, Allen R, et al. Towards a better definition of the restless legs syndrome. Mov Disord, 1995 (in press).
5. Akpinar S Restless legs syndrome treatment with dopaminergic drugs. Clin Neuropharmacol 1987;10:69-79.
6. Montplaisir J, Godbout R, Poirier G, Bedard MA Restless legs syndrome and periodic movements in sleep: physiopathology and treatment with L-dopa. Clin Neuropharmacol 1986;9:456-63.
7. Brodeur C, Montplaisir J, Godbout R, Marinier R. Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study. Neurology 1988;38:1845-8.
8. Walters AS, Hening WA, Kavey N, Chokroverty S, Gidro FS. A double-blind randomized crossover trial of bromocriptine and placebo in restless legs syndrome. Ann Neurol 1988;24:455-8.
9. Allen RP, Kaplan PW, Buchholz DW, Earley CJ, Walters JK. Double-blinded, placebo controlled comparison of high dose propoxyphene and moderate dose carbidopa/levodopa for treatment of periodic limb movements in sleep. Sleep Res 1992;21: 166.
10. Kaplan P, Allen R, Buchholz D, Walters J. A double-blind, placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene. Sleep 1993;16:717-23.
11. vonScheele C, Kempi V. Long-term effect of dopaminergic drugs in restless legs: a 2-year follow-up. Arch Neurol 1990;47: 1223-4.
12. Becker P, Jamieson A, Brown W. Dopaminergic agents in restless legs syndrome and periodic limb movements of sleep: response and complications of extended treatment in 49 cases. Sleep 1993;16:713-6.
13. Guilleminault C, Cetel C, Philip P. Dopaminergic treatment of restless legs and rebound phenomenon. Neurology 1993;43:445.
14. Coleman RM, Pollak CP, Weitzman ED. Periodic movements in sleep (nocturnal myoclonus): relation to sleep disorders. Ann Neurol 1980;8:416-21.
15. vonScheele C. Levodopa in restless legs. Lancet 1986;2:426-7.
16. Montplaisir J, Lorrain D, Godbout R. Restless legs syndrome and periodic leg movements in sleep: the primary role of dopaminergic mechanisms. Eur Neurol 1991;31:41-3.
17. Aghajanian GK, Bunney BS. Pre- and postsynaptic feedback mechanisms in central dopaminergic neurons. In: Seeman P, Brown GM, eds. Frontiers of neurology and neuroscience research. Toronto: University of Toronto Press, 1974:4-11.
18. Montastruc JL, Celsis P, Agniel A, et al. Levodopa-induced regional cerebral blood flow changes in normal volunteers and patients with parkinson's disease: lack of correlation with clinical or neuropsychological improvements. Mov Disord 1987;2: 279-89.
19. Sabatini U, Rascol O, Celsis P, et al. Subcutaneous apomorphine increases regional cerebral blood flow in parkinsonian patients via peripheral mechanisms. Br J Clin Pharmacol 1991;32:229-34.
20. Kebabian JW. Multiple classes of receptors in mamalian central nervous system: the involvement of dopamine-sensitive adenyIyl cyclase. Life Sci 1978;23:479-83.
21. Pieri L, Keller HH, Burkard W, DaPrada M. Effects of lisuride and LSD on cerebral monoamine systems and hallucinosis. Nature 1978;272:278-80.
22. Ohno Y, Sasa M, Takaori S. Co-existence of inhibitory dopamine D-1 and excitatory D-2 receptors on the same caudate nucleus neurons. Life Sci 1987;40:1937-45.
23. Iwatsubo K, Clouet DH. Effects of morphine and haloperidol on the electrical activity of rat nigrostriatal neruons. J Pharmacol Exp Ther 1977;202:429-36.
24. Scarivati E, Forchetti C, Ciancarelli G, Pacitti C, Agnoli A. Responsiveness of nigral neurons to the stimulation of striatal dopaminergic receptors in the rat. Life Sci 1980;26:1203-9.
25. Carlson JH, Bergstrom DA, Walters JR. Neurophysiological evidence that D-1 dopamine receptor blockade attenuates postsynaptic but not autoreceptor-mediated effects of dopamine agonists. Eur J Pharmacol 1986;23:237-51.
26. Mereu G, Casu M, Gessa GL. (-)-Sulpiride activates the firing rate and tyrosine hydroxylase activity of dopaminergic neurons in unanesthetized rats. Brain Res 1983;264:105-10.
27. Mereu G, Collu M, Ongini E, Biggio G, Gessa GL. SCH 23390, a selective dopamine D-1 antagonist, activates dopamine neurons but fails to prevent their inhibition by apomorphine. Eur J Pharmacol 1985;111:393-6.
28. Napier TC, Givens BS, Schulz DW, Bunney BS, Breese GR, Mailman RB. SCH 23390 effects on apomorphine-induced responses of nigral dopaminergic neurons. J Pharmacol Exp Ther 1986;236:838-45.